Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 3/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 11/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122429 | 0.82 | NTRK1 (0.67) | NTRK1BRAFALDH1A1PIP4K2APIP4K2B | |
| SCHEMBL1122223 | 0.81 | BRAF (0.61) | ESRRANTRK1BRAFRAF1ALDH1A1 | |
| SCHEMBL12857532 | 0.79 | BRAF (0.76) | BRAFRAF1 | |
| SCHEMBL1122188 | 0.77 | KMT2A (0.63) | ESRRANTRK1BRAFALDH1A1 | |
| SCHEMBL1122507 | 0.76 | BRAF (0.61) | ESRRANTRK1BRAFRAF1ALDH1A1 | |
| SCHEMBL27695812 | 0.72 | FABP7 (0.54) | ESRRAFABP7FABP3FABP5ALDH1A1 | |
| SCHEMBL1122961 | 0.72 | BRAF (0.53) | NTRK1BRAFALDH1A1 | |
| SCHEMBL1122184 | 0.69 | BRAF (0.56) | NTRK1BRAFALDH1A1 | |
| SCHEMBL1121851 | 0.69 | BRAF (0.72) | BRAF | |
| SCHEMBL1122275 | 0.68 | HSD17B1 (0.76) | FABP7FABP3FABP5ALDH1A1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831184-B1 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | WELLCOME TRUST LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| EP-1831184-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | The Wellcome Trust Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067466-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | THE WELLCOME TRUST LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | BRAF, RAF1, BCOR | ESRRA 887/4885NTRK1 342/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.